Patent intelligence · US
US 7205006
Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
Patent details — US 7205006
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 17, 2007
- Expiration
- Apr 12, 2027
- Applicant
- Prime Pharmaceutical Corporation
- Claims
- 3
- CPC classes
- A61K, A61K36/29, A61K8/14, A61K8/9789
Quick answer
US 7205006 (Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same) is held by Prime Pharmaceutical Corporation. Status: granted. Granted Apr 17, 2007. Expires Apr 12, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Prime Pharmaceutical Corporation
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K36/29, A61K8/14, A61K8/9789, A61K9/0014, A61K9/127
More from Prime Pharmaceutical Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12404275
Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
granted -
US 12383582
Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue inhibitors of matrix metalloproteinases
granted -
US 12377115
Combination immunotherapies for treatment of cancer
granted -
US 12365719
CD80 extracellular domain polypeptides and their use in cancer treatment
granted -
US 12319738
Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer
granted -
US 12304898
Quinolyl-containing compound and pharmaceutical composition, and use thereof
granted -
US 12234302
Chitosan derivatives and methods for preparing the same
granted -
US 12233119
Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
granted
Frequently asked questions
What is US patent 7205006?
US 7205006 (Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same) is held by Prime Pharmaceutical Corporation. Status: granted. Granted Apr 17, 2007. Expires Apr 12, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7205006?
Prime Pharmaceutical Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 127 pharmaceutical patents for this assignee.
When does US 7205006 expire?
Our index shows an expiration date of Apr 12, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.